Smoldering Multiple Myeloma

Abstract EN

Smoldering multiple myeloma (SMM) is an asymptomatic precursor stage of multiple myeloma (MM) characterized by clonal bone marrow plasma cells (BMPC) ≥ 10% and/or M protein level ≥ 30 g/L in the absence of end organ damage.

It represents an intermediate stage between monoclonal gammopathy of undetermined significance (MGUS) and symptomatic MM.

The risk of progression to symptomatic MM is not uniform, and several parameters have been reported to predict the risk of progression.

These include the level of M protein and the percentage of BMPC, the proportion of immunophenotypically aberrant plasma cells, and the presence of immunoparesis, free light-chain (FLC) ratio, peripheral blood plasma cells (PBPC), pattern of serum M protein evolution, abnormal magnetic resonance imaging (MRI), cytogenetic abnormalities, IgA isotype, and Bence Jones proteinuria.

So far treatment is still not recommended for SMM, because several trials suggested that patients with SMM do not benefit from early treatment.

However, the Mateos et al.

trial showed a survival benefit after early treatment with lenalidomide plus dexamethasone in patients with high-risk SMM.

This trial has prompted a reevaluation of early treatment in an asymptomatic patient population.